AT405740B
(de)
*
|
1996-12-13 |
1999-11-25 |
Immuno Ag |
Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen
|
EA003789B1
(ru)
|
1998-04-28 |
2003-10-30 |
Апплайд Резеч Системз Арс Холдинг Н.В. |
КОНЪЮГАТЫ ПОЛИОЛ-β-ИНТЕРФЕРОН
|
US7425541B2
(en)
*
|
1998-12-11 |
2008-09-16 |
Medarex, Inc. |
Enzyme-cleavable prodrug compounds
|
DK2193809T3
(en)
|
1999-02-22 |
2015-05-26 |
Univ Connecticut |
The albumin-free Factor VIII formulation
|
US6635676B2
(en)
*
|
1999-04-28 |
2003-10-21 |
Regents Of The University Of Michigan |
Non-toxic antimicrobial compositions and methods of use
|
US7655252B2
(en)
|
1999-04-28 |
2010-02-02 |
The Regents Of The University Of Michigan |
Antimicrobial nanoemulsion compositions and methods
|
IT1318484B1
(it)
*
|
2000-04-21 |
2003-08-25 |
Univ Roma |
Derivati di colina per il trattamento della malattia di alzheimer.
|
US7160540B2
(en)
|
2000-06-30 |
2007-01-09 |
Regents Of The University Of Minnesota |
Methods for detecting activity of clottings factors
|
US6423826B1
(en)
|
2000-06-30 |
2002-07-23 |
Regents Of The University Of Minnesota |
High molecular weight derivatives of vitamin K-dependent polypeptides
|
US20030211094A1
(en)
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
US20020120109A1
(en)
*
|
2000-07-07 |
2002-08-29 |
Samokhin Gennady P. |
Biologically active proteins
|
AU2002225681A1
(en)
*
|
2000-11-15 |
2002-05-27 |
Globe Immune, Inc. |
Yeast-dentritic cell vaccines and uses thereof
|
JP2010209109A
(ja)
*
|
2001-06-25 |
2010-09-24 |
Regents Of The Univ Of Michigan |
抗微生物ナノエマルジョンの組成物および方法
|
DE60236522D1
(de)
*
|
2001-07-11 |
2010-07-08 |
Maxygen Inc |
G-csf konjugate
|
US8008252B2
(en)
*
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
ES2516041T3
(es)
*
|
2001-10-10 |
2014-10-30 |
Ratiopharm Gmbh |
Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH)
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
SE0104186D0
(sv)
*
|
2001-12-12 |
2001-12-12 |
Darcy Birse |
Method and device
|
CN101700401B
(zh)
|
2002-01-18 |
2013-08-14 |
比奥根艾迪克Ma公司 |
具有用于共轭生物活性化合物的部分的聚亚烷基二醇
|
US20030149246A1
(en)
*
|
2002-02-01 |
2003-08-07 |
Russell John C. |
Macromolecular conjugates and processes for preparing the same
|
JP2005526505A
(ja)
*
|
2002-03-02 |
2005-09-08 |
エフ.ホフマン−ラ ロシュ アーゲー |
ヒトゲラチナーゼaのcドメイン及びポリエチレングリコールの接合体、その精製方法及び使用
|
MXPA04012496A
(es)
*
|
2002-06-21 |
2005-09-12 |
Novo Nordisk Healthcare Ag |
Glicoformos del factor vii pegilados.
|
DK1545613T3
(da)
*
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
CN102139114A
(zh)
|
2003-02-26 |
2011-08-03 |
尼克塔治疗公司 |
聚合物-因子viii部分缀合物
|
US7217794B2
(en)
*
|
2003-04-02 |
2007-05-15 |
Daiamed, Inc. |
Compounds and methods for treatment of thrombosis
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
EP1615945B1
(de)
|
2003-04-09 |
2011-09-28 |
BioGeneriX AG |
Glycopegylierungsverfahren und durch die verfahren hergestellte proteine/peptide
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
NZ544024A
(en)
*
|
2003-05-12 |
2009-06-26 |
Affymax Inc |
Novel poly(ethylene glycol) modified compounds and uses thereof
|
JP5048332B2
(ja)
*
|
2003-05-23 |
2012-10-17 |
ネクター セラピューティクス |
特定の原子配置を有するポリマー誘導体
|
US7947261B2
(en)
|
2003-05-23 |
2011-05-24 |
Nektar Therapeutics |
Conjugates formed from polymer derivatives having particular atom arrangements
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
DK1725249T3
(en)
*
|
2003-11-06 |
2014-03-17 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugating to ligands.
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
JP4738346B2
(ja)
*
|
2003-12-03 |
2011-08-03 |
ノヴォ ノルディスク アー/エス |
GlycoPEG化された第IX因子
|
US20050171002A1
(en)
*
|
2004-02-03 |
2005-08-04 |
Mohanty Dillip K. |
Polyoxyalkylene compound and method for making
|
ATE489105T1
(de)
|
2004-03-19 |
2010-12-15 |
Baxter Int |
Faktor ixa zur behandlung von blutungsstörungen
|
WO2005123140A2
(en)
*
|
2004-06-08 |
2005-12-29 |
Alza Corporation |
Preparation of macromolecular conjugates by four-component condensation reaction
|
AU2014280936B2
(en)
*
|
2004-06-30 |
2016-12-15 |
Nektar Therapeutics |
Polymer-factor ix moiety conjugates
|
ES2390082T5
(es)
*
|
2004-06-30 |
2018-01-19 |
Nektar Therapeutics |
Conjugados de resto de Factor IX y polímeros
|
US20080300173A1
(en)
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
US7381705B2
(en)
*
|
2004-09-29 |
2008-06-03 |
The Administrators Of The Tulane Educational Fund |
Inhibitors of hepatitis C virus
|
US20080176790A1
(en)
|
2004-10-29 |
2008-07-24 |
Defrees Shawn |
Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
|
AU2016203693B2
(en)
*
|
2004-11-12 |
2018-08-23 |
Bayer Healthcare Llc |
Site-directed modification of FVIII
|
EP1817336B1
(de)
*
|
2004-11-12 |
2019-01-09 |
Seattle Genetics, Inc. |
Auristatine mit einer aminobenzoesäureeinheit am n-ende
|
AU2013203348B2
(en)
*
|
2004-11-12 |
2016-03-03 |
Bayer Healthcare Llc |
Site-directed modification of FVIII
|
AU2012203813B2
(en)
*
|
2004-11-12 |
2013-10-24 |
Bayer Healthcare Llc |
Site-directed modification of FVIII
|
PL1824988T3
(pl)
|
2004-11-12 |
2018-01-31 |
Bayer Healthcare Llc |
Ukierunkowana na miejsce modyfikacja czynnika VIII
|
EP1835938B1
(de)
|
2004-12-27 |
2013-08-07 |
Baxter International Inc. |
Polymer-von willebrand faktor-konjugate
|
US9029331B2
(en)
|
2005-01-10 |
2015-05-12 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
WO2006076471A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Nobex Corporation |
Bnp conjugates and methods of use
|
US20070154992A1
(en)
|
2005-04-08 |
2007-07-05 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
JP5216580B2
(ja)
*
|
2005-05-25 |
2013-06-19 |
ノヴォ ノルディスク アー/エス |
グリコペグ化第ix因子
|
WO2007008848A2
(en)
*
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
|
US8343928B2
(en)
|
2005-07-07 |
2013-01-01 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus
|
US7395967B2
(en)
*
|
2005-07-21 |
2008-07-08 |
University Of Washington |
Methods and systems for counterbalancing a scanning beam device
|
US20070105755A1
(en)
*
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
EP1816201A1
(de)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
|
US7750116B1
(en)
*
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
US7982010B2
(en)
*
|
2006-03-31 |
2011-07-19 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
US7645860B2
(en)
*
|
2006-03-31 |
2010-01-12 |
Baxter Healthcare S.A. |
Factor VIII polymer conjugates
|
CA2647314A1
(en)
|
2006-03-31 |
2007-11-08 |
Baxter International Inc. |
Pegylated factor viii
|
US7985839B2
(en)
*
|
2006-03-31 |
2011-07-26 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
US20080242607A1
(en)
|
2006-07-21 |
2008-10-02 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
US20100075375A1
(en)
*
|
2006-10-03 |
2010-03-25 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
SI2068907T1
(en)
*
|
2006-10-04 |
2018-01-31 |
Novo Nordisk A/S |
Pegylated sugars and glycopeptides are associated with glycerol
|
CN105838699A
(zh)
|
2006-12-15 |
2016-08-10 |
巴克斯艾尔塔公司 |
具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
|
JP5448839B2
(ja)
|
2006-12-22 |
2014-03-19 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
インビボで長い半減期を有する修飾された凝固因子
|
WO2008082669A2
(en)
|
2006-12-27 |
2008-07-10 |
Nektar Therapeutics Al, Corporation |
Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage
|
BRPI0720619B1
(pt)
*
|
2006-12-27 |
2022-04-05 |
Nektar Therapeutics |
Composto de fator ix-poli(etileno glicol) com uma ligação liberável, método para preparar o mesmo e composição
|
KR20100016160A
(ko)
|
2007-04-03 |
2010-02-12 |
바이오제너릭스 에이지 |
글리코페길화 g―csf를 이용하는 치료 방법
|
US8187799B2
(en)
*
|
2007-04-26 |
2012-05-29 |
Bayer Healthcare Llc |
Stabilization of liquid solutions of recombinant protein for frozen storage
|
WO2008137747A1
(en)
|
2007-05-02 |
2008-11-13 |
The Regents Of The University Of Michigan |
Nanoemulsion therapeutic compositions and methods of using the same
|
MX2009013259A
(es)
|
2007-06-12 |
2010-01-25 |
Novo Nordisk As |
Proceso mejorado para la produccion de azucares de nucleotidos.
|
EP2486936A1
(de)
|
2007-06-13 |
2012-08-15 |
CSL Behring GmbH |
Eine Zusammensetzung enthaltend VWF und FVIII zur Vervendung in der Behandlung von Blutungsstörungen
|
WO2009012256A1
(en)
|
2007-07-16 |
2009-01-22 |
Genentech, Inc. |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
CL2008002085A1
(es)
|
2007-07-16 |
2008-11-21 |
Genentech Inc |
Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
|
US20090035848A1
(en)
*
|
2007-08-03 |
2009-02-05 |
Robert Hickey |
Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
|
US8173597B2
(en)
*
|
2007-11-09 |
2012-05-08 |
Baxter International Inc. |
Modified recombinant factor VIII and von Willebrand factor and methods of use
|
PL2247620T3
(pl)
|
2008-01-31 |
2017-08-31 |
Genentech, Inc. |
Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
|
US20130189239A1
(en)
|
2008-02-27 |
2013-07-25 |
Novo Nordisk A/S |
Conjugated Factor VIII Molecules
|
EP2297330A4
(de)
*
|
2008-06-04 |
2012-03-14 |
Bayer Healthcare Llc |
Fvii-muteine zur behandlung von morbus willebrand
|
CN103739712B
(zh)
|
2008-06-24 |
2016-10-05 |
德国杰特贝林生物制品有限公司 |
具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
|
US8143347B2
(en)
|
2008-10-15 |
2012-03-27 |
Baxter International Inc. |
Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
|
CA2740793A1
(en)
*
|
2008-11-03 |
2010-06-03 |
Haiyan Jiang |
Method for the treatment of hemophilia
|
MX339060B
(es)
|
2008-11-07 |
2016-05-09 |
Baxter Int |
Formulaciones del factor viii.
|
CA2743904A1
(en)
|
2008-11-17 |
2010-05-20 |
The Regents Of The University Of Michigan |
Cancer vaccine compositions and methods of using the same
|
ES2730800T3
(es)
|
2009-02-03 |
2019-11-12 |
Amunix Pharmaceuticals Inc |
Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
|
JP5908401B2
(ja)
|
2009-07-27 |
2016-04-26 |
バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated |
血液凝固タンパク質複合体
|
US8809501B2
(en)
|
2009-07-27 |
2014-08-19 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
CA2769244A1
(en)
|
2009-07-27 |
2011-02-03 |
Lipoxen Technologies Limited |
Glycopolysialylation of non-blood coagulation proteins
|
US8642737B2
(en)
|
2010-07-26 |
2014-02-04 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
CN104530182A
(zh)
|
2009-07-27 |
2015-04-22 |
利普森技术有限公司 |
非凝血蛋白的糖基多唾液酸化
|
AU2010290131C1
(en)
|
2009-08-24 |
2015-12-03 |
Amunix Operating Inc. |
Coagulation factor VII compositions and methods of making and using same
|
CA2782424C
(en)
|
2009-12-06 |
2021-07-27 |
Biogen Idec Hemophilia Inc. |
Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
|
GB201007356D0
(en)
|
2010-04-30 |
2010-06-16 |
Leverton Licence Holdings Ltd |
Conjugated factor VIIa
|
EA201291482A1
(ru)
|
2010-07-09 |
2013-10-30 |
Байоджен Айдек Хемофилия Инк. |
Химерные факторы коагуляции
|
US9611310B2
(en)
|
2010-07-09 |
2017-04-04 |
Bioverativ Therapeutics Inc. |
Systems for factor VIII processing and methods thereof
|
KR20130125789A
(ko)
*
|
2010-12-16 |
2013-11-19 |
노보 노르디스크 에이/에스 |
수성 인자ⅷ 용액
|
SG191298A1
(en)
|
2010-12-22 |
2013-07-31 |
Baxter Int |
Materials and methods for conjugating a water soluble fatty acid derivative to a protein
|
SI2717898T1
(sl)
|
2011-06-10 |
2019-07-31 |
Bioverativ Therapeutics Inc. |
Spojine prokoagulantov in metode za njihovo uporabo
|
ES2722209T3
(es)
|
2011-07-08 |
2019-08-08 |
Bioverativ Therapeutics Inc |
Polipéptidos quiméricos e híbridos del Factor VIII, y métodos de uso de los mismos
|
WO2013016454A1
(en)
|
2011-07-25 |
2013-01-31 |
Biogen Idec Hemophilia Inc. |
Assays to monitor bleeding disorders
|
CA2863328A1
(en)
|
2012-01-12 |
2013-07-18 |
Biogen Idec Ma Inc. |
Chimeric factor viii polypeptides and uses thereof
|
TR201816253T4
(tr)
|
2012-01-12 |
2018-11-21 |
Bioverativ Therapeutics Inc |
Faktör VIII terapisi almakta olan bireylerde faktör VIII'e karşı immünojenisiteyi azaltmanın yöntemleri.
|
EP2814502B1
(de)
|
2012-02-15 |
2017-09-13 |
CSL Behring GmbH |
Varianten des von-willebrand-faktors mit verbesserter faktor-viii-bindungsaffinität
|
CA2864126A1
(en)
|
2012-02-15 |
2013-08-22 |
Biogen Idec Ma Inc. |
Recombinant factor viii proteins
|
SI3564260T1
(sl)
|
2012-02-15 |
2023-02-28 |
Bioverativ Therapeutics Inc. |
Sestavki faktorja VIII in postopki njegove izdelave in uporabe
|
KR102057356B1
(ko)
|
2012-02-27 |
2019-12-18 |
아뮤닉스 파마슈티컬스, 인크. |
Xten 콘주게이트 조성물 및 그의 제조 방법
|
SG11201406492YA
(en)
*
|
2012-04-16 |
2014-11-27 |
Cantab Biopharmaceuticals Patents Ltd |
Optimised subcutaneous therapeutic agents
|
WO2013083858A1
(en)
|
2012-04-24 |
2013-06-13 |
Novo Nordisk A/S |
Compounds suitable for treatment of haemophilia
|
EP3693000B1
(de)
|
2012-06-08 |
2022-03-02 |
Bioverativ Therapeutics Inc. |
Prokoagulatorische verbindungen
|
AU2013270683A1
(en)
|
2012-06-08 |
2014-12-11 |
Biogen Ma Inc. |
Chimeric clotting factors
|
EP2870250B2
(de)
|
2012-07-06 |
2022-06-29 |
Bioverativ Therapeutics Inc. |
Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon
|
EA029685B1
(ru)
|
2012-07-11 |
2018-04-30 |
Амуникс Оперэйтинг Инк. |
Комплекс фактора viii с xten и белком фактора фон виллебранда и его применение (варианты)
|
EP2877202A4
(de)
|
2012-07-25 |
2016-06-01 |
Biogen Ma Inc |
Blutfaktorüberwachungstest und verwendungen davon
|
CA2888806A1
(en)
|
2012-10-18 |
2014-04-24 |
Biogen Idec Ma Inc. |
Methods of using a fixed dose of a clotting factor
|
EP3943102A1
(de)
|
2012-10-30 |
2022-01-26 |
Bioverativ Therapeutics Inc. |
Verfahren zur verwendung von fviii-polypeptid
|
ES2701076T3
(es)
|
2012-11-24 |
2019-02-20 |
Hangzhou Dac Biotech Co Ltd |
Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
|
HRP20231183T1
(hr)
|
2013-02-15 |
2024-01-05 |
Bioverativ Therapeutics Inc. |
Optimizirani gen faktora viii
|
TWI629993B
(zh)
|
2013-03-15 |
2018-07-21 |
美商生物化學醫療公司 |
因子viii多肽調配物
|
TWI788044B
(zh)
|
2013-03-15 |
2022-12-21 |
美商百歐維拉提夫治療公司 |
因子ix多肽調配物
|
DK2796145T3
(da)
|
2013-04-22 |
2018-01-29 |
Csl Ltd |
Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
|
EA201592022A1
(ru)
|
2013-06-28 |
2016-05-31 |
Байоджен Ма Инк. |
Расщепляемый тромбином линкер, содержащий xten, и его применение
|
US10947269B2
(en)
|
2013-08-08 |
2021-03-16 |
Bioverativ Therapeutics Inc. |
Purification of chimeric FVIII molecules
|
EP3033097B1
(de)
|
2013-08-14 |
2021-03-10 |
Bioverativ Therapeutics Inc. |
Faktor viii-xten fusionen sowie ihre verwendungen.
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
ES2967617T3
(es)
|
2013-12-06 |
2024-05-03 |
Bioverativ Therapeutics Inc |
Herramientas de farmacocinética poblacional y sus usos
|
CN114736305B
(zh)
|
2014-01-10 |
2023-05-05 |
比奥贝拉蒂治疗公司 |
因子viii嵌合蛋白及其用途
|
JP6609561B2
(ja)
|
2014-02-04 |
2019-11-20 |
バイオジェン・エムエイ・インコーポレイテッド |
翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用
|
US10464955B2
(en)
|
2014-02-28 |
2019-11-05 |
Hangzhou Dac Biotech Co., Ltd. |
Charged linkers and their uses for conjugation
|
ES2844232T3
(es)
|
2014-07-02 |
2021-07-21 |
CSL Behring Lengnau AG |
Factor de Von Willebrand modificado
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
CA2978374A1
(en)
|
2015-03-06 |
2016-09-15 |
Csl Behring Recombinant Facility Ag |
Modified von willebrand factor having improved half-life
|
WO2016188905A1
(en)
|
2015-05-22 |
2016-12-01 |
Csl Behring Recombinant Facility Ag |
Methods for preparing modified von willebrand factor
|
CN107787328B
(zh)
|
2015-05-22 |
2021-08-06 |
康诺贝林伦瑙有限公司 |
用于治疗血友病的截短的血管性血友病因子多肽
|
CA2991973C
(en)
|
2015-07-12 |
2021-12-07 |
Suzhou M-Conj Biotech Co., Ltd. |
Bridge linkers for conjugation of a cell-binding molecule
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
CN108472337B
(zh)
|
2015-08-03 |
2022-11-25 |
比奥贝拉蒂治疗公司 |
因子ix融合蛋白以及其制备和使用方法
|
SG10202106307UA
(en)
|
2015-11-13 |
2021-07-29 |
Takeda Pharmaceuticals Co |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
CN108602876B
(zh)
|
2015-11-13 |
2022-07-05 |
武田药品工业株式会社 |
用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
|
EP3400238B1
(de)
|
2016-01-07 |
2021-05-19 |
CSL Behring Lengnau AG |
Mutierter von-willebrand-faktor
|
SG10201912498YA
(en)
|
2016-01-07 |
2020-02-27 |
CSL Behring Lengnau AG |
Mutated truncated von willebrand factor
|
HRP20221089T1
(hr)
|
2016-02-01 |
2022-11-25 |
Bioverativ Therapeutics Inc. |
Optimizirani geni faktora viii
|
WO2017222337A1
(ko)
|
2016-06-24 |
2017-12-28 |
재단법인 목암생명과학연구소 |
Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
|
DK3538133T3
(da)
|
2016-11-11 |
2021-04-19 |
CSL Behring Lengnau AG |
Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
|
TW201828974A
(zh)
|
2016-11-11 |
2018-08-16 |
瑞士商Csl貝林重組技能公司 |
用於血管外施予以治療或預防凝血疾病之截短型類血友病因子(von Willebrand factor)多肽類
|
KR20220150408A
(ko)
|
2016-11-14 |
2022-11-10 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
KR20190091292A
(ko)
|
2016-12-02 |
2019-08-05 |
바이오버라티브 테라퓨틱스 인크. |
응고 인자에 대한 면역 내성 유도 방법
|
IL308416A
(en)
|
2016-12-02 |
2024-01-01 |
Bioverativ Therapeutics Inc |
Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
|
SG11202000764RA
(en)
|
2017-08-09 |
2020-02-27 |
Bioverativ Therapeutics Inc |
Nucleic acid molecules and uses thereof
|
BR112020015228A2
(pt)
|
2018-02-01 |
2020-12-29 |
Bioverativ Therapeutics Inc. |
Uso de vetores lentivirais que expressam fator viii
|
TW202014181A
(zh)
|
2018-04-04 |
2020-04-16 |
美商希吉隆醫療公司 |
可植入顆粒及相關方法
|
JP2021523878A
(ja)
|
2018-05-18 |
2021-09-09 |
バイオベラティブ セラピューティクス インコーポレイテッド |
血友病aを処置する方法
|
EP3823985A1
(de)
|
2018-07-16 |
2021-05-26 |
Baxalta Incorporated |
Gentherapie von hämophilie a unter verwendung viraler vektoren, die für rekombinante fviii-varianten mit erhöhter expression codieren
|
JP2021533753A
(ja)
|
2018-08-09 |
2021-12-09 |
バイオベラティブ セラピューティクス インコーポレイテッド |
核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
|
UY38389A
(es)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
Dispositivos implantables para terapia celular y métodos relacionados
|
TW202039546A
(zh)
|
2019-01-16 |
2020-11-01 |
美商巴克斯歐塔公司 |
用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
|
AU2020298233A1
(en)
|
2019-06-19 |
2022-01-20 |
Bioverativ Therapeutics Inc. |
Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density
|
US20230023826A1
(en)
|
2019-12-12 |
2023-01-26 |
Takeda Pharmaceutical Company Limited |
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
CN117858895A
(zh)
|
2021-06-14 |
2024-04-09 |
武田药品工业株式会社 |
使用表达增强的编码重组fviii变体的病毒载体的血友病a基因疗法
|
CA3229323A1
(en)
|
2021-08-23 |
2023-03-02 |
Ajay MAGHODIA |
Optimized factor viii genes
|
AU2022355088A1
(en)
|
2021-09-30 |
2024-05-16 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|
WO2024081309A1
(en)
|
2022-10-11 |
2024-04-18 |
Sigilon Therapeutics, Inc. |
Engineered cells and implantable elements for treatment of disease
|